Asahi Kasei Corporation, with consolidated sales of US$10 billion, provides innovative solutions based in chemistry and materials science to a diverse range of markets including fibers, chemicals, consumer products, housing, construction, electronics, and health care. On October 1, 2003, all core operations were transferred to seven wholly owned constituent corporations as autonomous operating business units. Asahi Kasei Corporation, as the parent company, functions as a holding company for group operations. An Independent Businesses Group not included in the constituent corporations provides group services
| Contact Details: |
| 535 Madison Avenue, 33rd Floor |
| New York |
| New York |
| 10022 |
| United States of America |
| Tel: | 1-212-371-9900 |
| Fax: | 1-212-371-9050 |
| Email: | extech@om.asahi-kasei.co.jp |
| WWW: | www.asahi-kasei.co.jp/

|
|
Loading...
|
Recent Publications by Asahi Kasei Corporation: |  |
Amelioration of endothelial damage/dysfunction is a possible mechanism for the neuroprotective effects of Rho-kinase inhibitors against ischemic brain damage.
We investigated the neuroprotective effects of fasudil's active... | 3rd September, 2009
| Research Center, Asahi Kasei Pharma Corporation 632-1, Mifuku,
| Brain Res Bull. 2009 Aug 31.
DOI Direct Link |
Hydrothermal formation of tobermorite studied by in situ X-ray diffraction under autoclave condition.
Hydrothermal formation of tobermorite from a pre-cured cake has been... | 29th August, 2009
| Analysis and Simulation Center, Asahi-KASEI Corporation, Japan.
| J Synchrotron Radiat. 2009 Sep;16(Pt 5):683-6. Epub 2009 Jul 2.
DOI Direct Link |
Discovery of selective PDE4B inhibitors.
In this study the first PDE4B selective inhibitor is described.... | 22nd August, 2009
| Pharmaceuticals Research Center, Asahi Kasei Pharma Corporation, 632-1
| Bioorg Med Chem Lett. 2009 Jun 15;19(12):3174-6. Epub 2009 May 3.
DOI Direct Link |
Identification of biofoulant of membrane bioreactors in soluble microbial products.
To reveal primary biofoulant in soluble microbial products (SMP) and/or... | 15th July, 2009
| Microza & Water Processing Division, Asahi Kasei Chemicals Co., Ltd.,
| Water Res. 2009 Sep;43(17):4356-62. Epub 2009 Jun 25.
DOI Direct Link |
Collaborative work on evaluation of ovarian toxicity. 13) Two- or four-week repeated dose studies and fertility study of PPAR alpha/gamma dual agonist in female rats.
The main focus of this study was to determine the optimal dosing period in... | 1st July, 2009
| Laboratory for Safety Assessment & ADME, Pharmaceuticals Research Center,
| J Toxicol Sci. 2009;34 Suppl 1:SP137-46.
|
→View more Asahi Kasei Corporation research publications. |
BioPortfolio Ltd provides targeted e-mail address lists for the life science sector - we can enable you to contact around 21 individuals from Asahi Kasei Corporation using this service.
Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 547 times since April 2007, the link to the organisation's website has been followed 60 times
Recent Search Terms used to find this page: company profile pdf jp | Asahi Kasei Chemicals Corporation mail | Asahi Kasei Corporation | om asahi kasei co jp | Asahi Medical Group - @om.asahi-kasei.co.jp | asahi research Center corp tel | Asahi Kasei Chemicals Corporation email @asahi-kasei.co.jp | asahi kasei fiber pdf | patent soluble human thrombomodulin Asahi Kasei pharma | Asahi Kasei Pharma Corporation | .
Search for more companies in New York
Search for more companies in New York
This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for
Asahi Kasei Corporation